Ibrahim Azar1, Gurjiwan Virk1, Saghi Esfandiarifard1, Ali Wazir1, Syed Mehdi2. 1. Department of Internal Medicine, Albany Medical Center, Albany, NY, USA. 2. Division of Hematology-Oncology, Department of Internal Medicine, Stratton Veterans Affairs Medical Center, Albany, NY, USA.
Abstract
BACKGROUND: Metastatic pancreatic cancer (MPC) is associated with an extremely high mortality. Current NCCN guidelines recommend systemic therapy, as it is superior to best supportive care. Undertreatment of MPC continues to be an issue. Recent treatment and survival data of MPC in Veterans' Affairs' (VA) hospitals have not been published. The relationship between MPC treatment and survival and the American College of Surgeons' (ACS) Committee on Cancer (CoC) accreditation in VA hospitals has not been studied. METHODS: Nationwide data from the National Veterans Affairs Cancer Cube Registry was analyzed. In total, 6,775 patients were diagnosed with MPC between 2000 and 2014. CoC accreditation of each VA hospital was obtained using the ACS website. RESULTS: MPC constitutes 52.31% of all pancreatic cancer diagnosed (6,775/12,951 cases). The near totality was men (97.44%). The above 70 years age group and the 60-70 years age group were the most common ages at diagnosis with 39.39% and 38.02% respectively. The proportion of early-onset pancreatic cancer (EOPC) was 2.84%. When compared to all stages of pancreatic cancer, stage IV pancreatic cancer had a lower proportion of cancer originating from the head of the pancreas (39.33% versus 50.63%) and more originating from the tail (17.99% versus 13.39%). Tumors originating from head of the pancreas are more likely to cause biliary symptoms and thus are more likely to be caught at an earlier stage. Overall, treatment rate in the VA at the national level with first-line chemotherapy was 37.61%. The rate of treatment over the years has increased in a linear fashion from 33.01% in 2000 to 41.95% in 2014. This has corresponded with an increase of 1-5 years survival of 9.29% in 2000 to 22.99% in 2014 and 5-10 years survival from 0.96% in 2000 to 6.00% in 2012. Treatment rates in CoC-accredited and non-CoC accredited VA hospitals were similar (38.94% and 38.12%, respectively). Survival rates in CoC-accredited and non-COC accredited VAs were similar with a 1-5 years survival rate of 8.89% and 8.57%, respectively. CONCLUSIONS: Treatment and survival of MPC have risen significantly in the past decade at VA hospitals. CoC accreditation is not associated with a change in treatment or survival rates.
BACKGROUND: Metastatic pancreatic cancer (MPC) is associated with an extremely high mortality. Current NCCN guidelines recommend systemic therapy, as it is superior to best supportive care. Undertreatment of MPC continues to be an issue. Recent treatment and survival data of MPC in Veterans' Affairs' (VA) hospitals have not been published. The relationship between MPC treatment and survival and the American College of Surgeons' (ACS) Committee on Cancer (CoC) accreditation in VA hospitals has not been studied. METHODS: Nationwide data from the National Veterans Affairs Cancer Cube Registry was analyzed. In total, 6,775 patients were diagnosed with MPC between 2000 and 2014. CoC accreditation of each VA hospital was obtained using the ACS website. RESULTS: MPC constitutes 52.31% of all pancreatic cancer diagnosed (6,775/12,951 cases). The near totality was men (97.44%). The above 70 years age group and the 60-70 years age group were the most common ages at diagnosis with 39.39% and 38.02% respectively. The proportion of early-onset pancreatic cancer (EOPC) was 2.84%. When compared to all stages of pancreatic cancer, stage IV pancreatic cancer had a lower proportion of cancer originating from the head of the pancreas (39.33% versus 50.63%) and more originating from the tail (17.99% versus 13.39%). Tumors originating from head of the pancreas are more likely to cause biliary symptoms and thus are more likely to be caught at an earlier stage. Overall, treatment rate in the VA at the national level with first-line chemotherapy was 37.61%. The rate of treatment over the years has increased in a linear fashion from 33.01% in 2000 to 41.95% in 2014. This has corresponded with an increase of 1-5 years survival of 9.29% in 2000 to 22.99% in 2014 and 5-10 years survival from 0.96% in 2000 to 6.00% in 2012. Treatment rates in CoC-accredited and non-CoC accredited VA hospitals were similar (38.94% and 38.12%, respectively). Survival rates in CoC-accredited and non-COC accredited VAs were similar with a 1-5 years survival rate of 8.89% and 8.57%, respectively. CONCLUSIONS: Treatment and survival of MPC have risen significantly in the past decade at VA hospitals. CoC accreditation is not associated with a change in treatment or survival rates.
Authors: Avo Artinyan; Perry A Soriano; Christina Prendergast; Tracey Low; Joshua D I Ellenhorn; Joseph Kim Journal: HPB (Oxford) Date: 2008 Impact factor: 3.647
Authors: Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar Journal: J Clin Oncol Date: 2007-04-23 Impact factor: 44.544
Authors: Sara Raimondi; Patrick Maisonneuve; J-Matthias Löhr; Albert B Lowenfels Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-09 Impact factor: 4.254
Authors: Thomas L Sutton; Aaron Grossberg; Frederick Ey; Eileen M O'Reilly; Brett C Sheppard Journal: Cancer Biol Ther Date: 2021-10-25 Impact factor: 4.742
Authors: Fouad Choueiry; Molly Torok; Reena Shakya; Kriti Agrawal; Anna Deems; Brooke Benner; Alice Hinton; Jami Shaffer; Bradley W Blaser; Anne M Noonan; Terence M Williams; Mary Dillhoff; Darwin L Conwell; Phil A Hart; Zobeida Cruz-Monserrate; Xue-Feng Bai; William E Carson; Thomas A Mace Journal: J Immunother Cancer Date: 2020-06-23 Impact factor: 13.751
Authors: Marina Emelyanova; Elena Pudova; Darya Khomich; George Krasnov; Anna Popova; Ivan Abramov; Vladimir Mikhailovich; Maxim Filipenko; Sofia Menshikova; Sergey Tjulandin; Ilya Pokataev Journal: Ther Adv Med Oncol Date: 2022-03-15 Impact factor: 8.168
Authors: Justin M Lebenthal; Junting Zheng; Paul A Glare; Eileen M O'Reilly; Andrew C Yang; Andrew S Epstein Journal: Cancer Date: 2021-01-20 Impact factor: 6.860
Authors: Dominique Farge; Barbara Bournet; Thierry Conroy; Eric Vicaut; Janusz Rak; George Zogoulous; Jefferey Barkun; Mehdi Ouaissi; Louis Buscail; Corinne Frere Journal: Cancers (Basel) Date: 2020-03-06 Impact factor: 6.639
Authors: Can Yurttas; Philipp Horvath; Imma Fischer; Christoph Meisner; Silvio Nadalin; Ingmar Königsrainer; Alfred Königsrainer; Stefan Beckert; Markus W Löffler Journal: Ann Surg Oncol Date: 2021-06-15 Impact factor: 5.344